| Third Advances Against Aspergillosis Meeting 2008. | |
| | |
MedLine Citation:
|
PMID: 19053897 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
On 16-19 January 2008, the Third Advances Against Aspergillosis Meeting took place in Miami Beach, FL, USA. There were 351 registrants from 26 countries. The two earlier meetings had taken place in San Francisco, CA, 2004 and in Athens, Greece, 2006, and the series has become the place for scientists and clinicians to be updated on developments relevant to all aspects of this fungal genus. |
| | |
Authors:
|
David A Stevens; Karl V Clemons |
Related Documents
:
|
12413567 - Minimizing rivalry in san miniato. 10798857 - 7th international hugo mutation database meeting, october 19, 1999, san francisco, usa. 21613647 - Justification for a home-based education programme for kidney patients and their social... 21040757 - The life and scientific contributions of keith l. parker, 1953-2008. 21856127 - Ketogenic diets: where do we go from here? 3401107 - Residency ethics teaching. a critique of current trends. |
Publication Detail:
|
Type: Congresses |
Journal Detail:
|
Title: Expert review of anti-infective therapy Volume: 6 ISSN: 1744-8336 ISO Abbreviation: Expert Rev Anti Infect Ther Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2008-12-04 Completed Date: 2009-02-06 Revised Date: 2009-03-03 |
Medline Journal Info:
|
Nlm Unique ID: 101181284 Medline TA: Expert Rev Anti Infect Ther Country: England |
Other Details:
|
Languages: eng Pagination: 851-3 Citation Subset: IM |
Affiliation:
|
Division of Infectious Disease, Department of Medicine, Santa Clara Valley Medical Center, 751 South Bascom Avenue, San Jose, CA 95128-2699, USA. stevens@stanford.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aspergillosis
/
drug therapy,
epidemiology,
immunology,
microbiology* Aspergillus / pathogenicity*, physiology Florida Humans |
| Comments/Corrections | |
Erratum In:
|
Expert Rev Anti Infect Ther. 2009 Mar;7(2):242 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Linezolid for the treatment of drug-resistant infections.
Next Document: Entecavir monotherapy for lamivudine-refractory chronic hepatitis B.